Thymidylate, a key precursor of DNA,' is synthesized by the tetrahydrofolate-dependent methylation of deoxyuridylate or by the phosphorylationl of thymidine via thymidine kinase (3) . The former reaction, catalyzed by thymidylate synthetase, has been the subject of several investigations (4) (5) (6) including that of Wahba and Friedkin (7, 8) The present investigation is concerned with the characterization of thymidylate synthetase from human leukocytes and with the levels of this en-* This investigation was supported by a grant (P-203) from the American Cancer Society. Preliminary reports of this work have appeared elsewhere (1, 2 (9) and used to phosphorylate 3'-acetyl-FUDR in the synthesis of FUDRP according to the procedure of Remy and Heidelberger (10); tetrahydrofolic acid and 5-methyl tetrahydrofolic acid prepared by Mr. P. P. K. Ho and Mr. J. Mangum, respectively, using previously described procedures (11, 12) ; and 5-fluorouracil, 5-diazouracil, 6-mercaptopurine ribonucleoside, and 5-iododeoxyuridine.'0
Criteria for the selection of clinical material used in this study have been give in a previous paper of this series (13) . Detailed hematological data on the present patients including course of therapy are presented in a later table.
Leukocytes were isolated by a method described previously (13) , suspended in 3 vol of cold 0.05 M barbital buffer, pH 7.6, and homogenized in a Virtis "45" homogenizer at 45,000 rpm for 3 minutes. After centrifugation of the homogenate for 15 minutes at 10,900 X g, the sediment was discarded, and the supernatant fraction was used for the enzyme assays. Protein was determined by the biuret method with bovine serum albumin as the standard. Deoxycytidylate deaminase was determined by the method of Maley and Maley (14) .
Assay for thymidylate synthetase. The assay used in this study, based upon the incorporation of HC'4HO into thymidylate, is adapted from several procedures described previously (15) (16) (17) (18) 
RESULTS
Properties of thymidylate synthetase. With the HC14HO assay system, it was established that the rate of the reaction catalyzed by the leukocyte thymidylate synthetase was proportional to enzyme concentration and to time. The pH-activity curve showed a rather broad optimum with the maximum centered around pH 6.5 ( Figure 1 ). In the leukocyte homogenate, the enzyme was stable at 40 C for 24 hours, and 50%o of the activity was retained when a dialyzed 40 to 60%o ammonium sulfate fraction was stored at -200 C for 2 weeks.
A component study for Reaction 1 is presented in Table I Table II . Thus, addition of 10-2 M ATP to the otherwise noninhibitory FUDR at 10-4 M resulted in complete inhibition of enzyme activity. ATP at this level had no effect on the synthetase activity.
The interrelationship of thymidylate synthetase and dihydrofolic reductase has been outlined in Equation 2 . The coupling of synthetase and re- Figure 1 . When dCMP was deaminated, the product was identified as dUMP by paper chromatography and by its ability to serve as a substrate in the thymidylate synthetase reaction.
The specificity of the deaminase system for various cytosine derivatives is summarized in Table  III . In addition to the deoxyribonucleotide (dCMP), deamination occurred with the deoxyribonucleoside (deoxycytidine), the 5-methyl deoxyribonucleoside, and the ribonucleoside (cytidine Although we had reported in a preliminary communication (2) that thymidylate synthetase could not be found in acute leukemic leukocytes, the present studies using C14-formaldehyde of a higher specific activity have shown that a low level of thymidylate synthetase (0.07 munmole per hour per mg protein) could be detected in four out of the seven acute leukemic patients recorded in Table IV . There was no apparent correlation between patients with the detectable enzyme levels with the type of acute leukemia, percentage of blasts, or therapy.
Thymidylate synthetase could not be detected in the cells of 12 normal subjects or of eight patients with chronic lymplhocytic leukemia. Furthermore, no synthetase activity could be detected in purified fractions from these cells that might be expected to contain the enzyme. For example, the leukocytes from 8 U of normal blood were pooled and fractionated according to the procedure used for the purification of thymidylate synthetase. Both the crude lysate and the 40 to 60%o ammonium sulfate fraction were devoid of any measurable amount of synthetase.
Thymidylate synthetase was also found in two nonleukemic patients with marked leukocytosis. One patient had a leukemoid reaction secondary to carcinoma, and the second had infectious mononucleosis with a leukocyte count of 27,000. Inhibition of thymidylate synthetase has been demonstrated with FUDRP, the deoxyribonucleotide of fluorouracil; the deoxyribonucleoside, FUDR, is ineffective. The latter compound, however, may merit attention in the treatment of chronic myelocytic leukemia, since it is more readily available than FUDRP and, being nonphosphorylated, passes through cell membranes easily and can be phosphorylated within the cell to yield FUDRP. The enzymatic phosphorylation of FUDR, and an alternate pathway for the synthesis of FUDRP from fluorouracil, have been studied in ascites tumor cells by Reichard (20) .
The extremely low level of thymidylate synthetase in the leukocyte presents some difficulties in its detection, but this has been minimized by the use of a C14-labeled substrate having a high specific activity. The fact that thymidylate synthetase activity occurs at a level two to three times lower than that of other relevant enzymes which have been studied, e.g., dihydroorotic dehydrogenase (21) and dihydrofolic reductase (13) , supports the suggestion (22) that the reaction catalyzed by this enzyme is probably the rate-limiting step in the biosynthesis of DNA. It has been found previously that when thymine-2-C14 was added to suspensions of leukemic leukocytes, 91 %o of the labeled material was recovered in DNA, and none was found in the acid-soluble nucleotide pool (23) . The administration of other labeled purine and pyrimidine precursors, however, resulted in the labeling of acid-soluble nucleotides. This would suggest that in the leukocyte the pool of free thymidylate is very small and that newly synthesized TMP is converted rapidly to the triphosphate and thence incorporated into DNA via the DNA-polymerase reaction; this suggestion has been substantiated recently by the findings of Bianchi (3) .
Information about cellular proliferative activity obtained by cytological and cytochemical techniques in the intact leukocyte, as well as thymidylate synthetase and dihydrofolic reductase levels, is summarized in Table V . Good agreement exists among the various criteria applied to cellular proliferative activity. Chronic myelocytic leukemic cells have the highest rate of thymidylate synthesis (23) (24) (25) as judged from the incorporation of labeled precursors (formate, formaldehyde, or thymidine). Similarly, we have found the highest levels of thymidylate synthetase activity in these cells. The mitotic index of chronic myelocytic leukemia bone marrow is also higher than in acute leukemia, chronic lymphocytic leukemia, or in normal cells (26) (27) (28) .
Acute leukemia appears to be heterogeneous inasmuch as the leukocytes of some, but not all, of the patients a) incorporate C14-formaldehyde (24, 27) 
